The protease of human T-cell leukemia virus type-1 is a potential therapeutic target

Current Pharmaceutical Design

Volumn 13, Issue 12, 2007, Pages 1285-1294

  Tözsér, József ^a   Weber, Irene T ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

HIV 1; HTLV 1; Life cycle; Proteolysis; Viral protease

Indexed keywords

ANTIVIRUS AGENT; IB 268; IB 269; JG 365; MES 13 099; MES 13099; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

BINDING SITE; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; REVIEW; SPINAL CORD DISEASE; T CELL LEUKEMIA; VIRUS MORPHOLOGY; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ASPARTIC ENDOPEPTIDASES; DRUG DELIVERY SYSTEMS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MOLECULAR SEQUENCE DATA; PROTEASE INHIBITORS;

EID: 34248391447     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618849     Document Type: Review

References (45)

1. Burmeister T. Oncogenic retroviruses in animals and humans. Rev Med Virol 2001; 11: 369-80.
2. Calattini S, Chevalier SA, Duprez R, Bassot S, Froment A, Mahieux R, et al. Discovery of a new human T-cell lymphotropic virus (HTLV-3 in Central Africa. Retrovirology 2005; 2: 30.
3. Johnson JM, Harrod R, Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). Int J Exp Pathol 2001; 82: 135-47.
4. Gallo RC. Human retroviruses after 20 years: A perspective from the past and prospects for their future control. Immunol Rev 2002; 185: 236-65.
5. Araujo A, Hall WW. Human T-lymphotropic virus type II and neurological disease. Ann Neurol 2004; 56:10-9.
6. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003; 9: 29-35
7. Sheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: Safety and possible efficacy. Neurology 1993; 43: 2125-9.
8. Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Des 2003; 9: 1803-15.
9. Rodriguez-Barrios F, Gago F. HIV protease inhibition: Limited recent progress and advances in understanding current pitfalls. Curr Top Med Chem 2004; 4: 991-1007.
10. Louis JM, Oroszlan S, Tozser J. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase. J Biol Chem 1999; 274: 6660-6.
11. Shuker SB, Mariani VL, Herger BE, Dennison KJ. Understanding HTLV-I protease. Chem Biol 2003; 10: 373-80.
12. Daenke S. Human T-cell leukemia virus type I (HTLV-I) retropepsin. In: Barrett AJ, Rowlings ND, Woessner JF Eds, Handbook of proteolytic enzymes, 2nd ed. Elsevier Science Ltd. London 2004; 166-9.
13. Oroszlan S, Luftig RB. Retroviral proteinases. Curr Topics Microbiol Immunol 1990; 157: 153-85.
14. Mitchell MS, Tozser J, Pricler G, Lloyd PA, Auth A, Derse D. Synthesis, processing and composition of the virion-associated HTLV-1 reverse transcriptase. J Biol Chem 2006; 281: 3964-71.
15. Daenke S, Schramm HJ, Bangham CR. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding. J Gen Virol 1994; 75: 2233-9.
16. Trentin B, Rebeyrotte N, Mamoun RZ. Human T-cell leukemia virus type 1 reverse transcriptase (RT) originates from the pro and pol open reading frames and requires the presence of RT-RNase H (RH) and RT-RH-integrase proteins for its activity. J Virol 1998; 72: 6504-10.
17. Mariani VL, Shuker SB. Identification of the RT-RH/IN cleavage site of HTLV-I. Biochem Biophys Res Commun. 2003; 300: 268-70.
18. Wlodawer A, Gustchina A. Structural and biochemical studies of retroviral proteases. Biochim Biophys Acta 2000; 1477: 16-34.
19. Li M, Laco GS, Jaskolski M, Rozycki J, Alexandros J, Wlodawer A, et al. Crystal structure of human T-cell leukemia virus protease, a novel target for anti-cancer drug design. Proc Natl Acad Sci USA 2005; 102: 8332-7.
20. Tozser J, Zahuczky G, Bagossi P, Louis JM, Copeland TD, Oroszlan S, et al. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases. Eur J Biochem 2000; 267: 6287-95.
21. Hayakawa T, Misumi Y, Kobayashi M, Yamamoto Y, Fujisawa Y. Requirement of N- and C-terminal regions for enzymatic activity of human T-cell leukemia virus type I protease. Eur J Biochem 1992; 206: 919-25.
22. Herger BE, Mariani VL, Dennison K, Shuker SB. The 10 C-terminal residues of HTLV-I protease are not necessary for enzymatic activity. Biochem Biophys Res Commun 2004; 320: 1306-8.
23. Rose JR, Salto R, Craik CS. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J Biol Chem 1993; 268: 11939-45.
24. Mildner AM, Rothrock DJ, Leone JW, Bannow CA, Lull JM, Reardon IM, et al. The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 1994; 33: 9405-13.
25. Davis DA, Newcomb FM, Starke DW, Ott DE, Mieyal JJ, Yarchoan R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J Biol Chem 1997; 272: 25935-40.
26. Davis DA, Brown CA, Newcomb FM, Boja ES, Fales HM, Kaufman J, et al. Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation. J Virol 2003; 77: 3319-25.
27. Parker SD, Hunter E. Activation of the Mason-Pfizer monkey virus protease within immature eapsids in vitro. Proc Natl Acad Sci USA 2001; 98: 14631-6.
28. Kubota S, Oroszlan S. The role of redox signaling in the processing of Gag polyprotein in immature retrovirus. In: Pasquier C Ed, XI Biennial Meeting of the Society for Free Radical Res International (Paris, France, July 16-20, 2002). Monduzzi Editore Italy 2003; 193-7.
29. Wu J, Adomat JM, Ridky TW, Louis JM, Leis J, Harrison RW, Weber IT. Structural basis for specificity of retroviral proteases. Biochemistry 1998; 37: 4518-26.
30. Kadas J, Weber IT, Bagossi P, Miklossy G, Boross P, Oroszlan S, et al Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. J Biol Chem 2004; 279: 27148-57.
31. Feher A, Weber IT, Bagossi P, Boross P, Mahalingam B, Louis JM, et al. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 2002; 269: 4114-20.
32. Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/ lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66: 2288-95.
33. Schechter I, Berger A. On the size of the active site in proteases. I. papain. Biochem Biophys Res Commun 1967; 27: 157-62.
34. Bagossi P, Sperka T, Feher A, Kadas J, Zahuczky G, Miklossy G, et al. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J Virol 2005; 79: 4213-8.
35. Phylip LH, Richards AD, Kay J, Kovalinka J, Strop P, Blaha I, et al. Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. Biochem Biophys Res Commun 1990; 171: 439-44.
36. Tozser J, Bagossi P, Weber IT, Louis JM, Copeland TD, Oroszlan S. Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. J Biol Chem 1997; 272: 16807-14.
37. Ding YS, Rich DH, Ikeda RA. Substrates and inhibitors of human T-cell leukemia virus type I protease. Biochemistry 1998; 37: 17514-8.
38. Bagossi P, Kadas J, Miklossy G, Boross P, Weber IT, Tozser J. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J Virol Methods 2004; 119: 87-93.
39. Derse D, Hill SA, Lloyd PA, Chung Hk, Morse BA. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J Virol 2001; 75: 8461-8.
40. Pettit SC, Sanchez R, Smith T, Wehbie R, Derse D, Swanstrom R. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells. AIDS Res Hum Retroviruses 1998; 14: 1007-14.
41. Heidecker G, Hill S, Lloyd PA, Derse D. A novel protease processing site in the transframe protein of human T-cell leukemia virus type 1 PR76(gag-pro) defines the N terminus of RT. J Virol 2002; 76: 13101-5.
42. Akaji K, Teruya K, Aimoto S. Solid-phase synthesis of HTLV-1 protease inhibitors containing hydroxyethylamine dipeptide isostere. J Org Chem 2003; 68: 4755-63.
43. Advani AS. FLT3 and acute myelogenous leukemia: Biology, clinical significance and therapeutic applications. Curr Pharm Des 2005; 11(26): 3449-57.
44. Schmidt-Arras D, Schwable J, Bohmer FD, Serve H. Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 2004; 10(16): 1867-83.
45. Yusa K, Harada S. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr Pharm Des 2004; 10(32): 4055-64.